Onyx Pharmaceuticals Inc. (ONXX) reported a fourth-quarter net loss of $42.92 million, or $0.64 per share, compared to net income of $216.68 million or $3.16 per share in the year ago quarter. The company recorded contingent consideration expense of $2.9 million, compared to a benefit of $116.7 million in the prior year quarter.
Non-GAAP net loss for the quarter was $23.99 million, or $0.36 per share, compared to net income of $105.30 million or $1.50 per share last year. Analysts polled by Thomson Reuters expected the company to report a loss of $0.75 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter was $127.9 million, down from $237.0 million in the year ago quarter. Revenue from the Nexavar collaboration agreement fourth quarter of 2012 was $72.9 million, compared to $76.8 million last year. Contract revenue from collaborations plunged to $1.50 million from $160.21 million last year.
Eighteen analysts had consensus revenue estimate of $113.17 million for the quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.